What happens in the body when we are hungry and see and smell food? A team of researchers at the DZD and the Max Planck Institute for Metabolism Research has now been able to show in mice that adaptations in the liver mitochondria take place after only a few minutes. Stimulated by the activation of a group of nerve cells in the brain, the mitochondria of the liver cells change and prepare the liver for the adaptation of the sugar metabolism. The findings, published in the journal Science, could open up new avenues for the treatment of type 2 diabetes.

The researchers fed hungry mice that could only see and smell the food without eating it. After just a few minutes, the researchers analysed the mitochondria in the liver and found that processes normally stimulated by food intake were activated.

Mitochondria in the liver get ready

The studies show that it is sufficient for the mice to see and smell food for a few minutes to influence the mitochondria in the liver cells. This is mediated by a previously uncharacterised phosphorylation in a mitochondrial protein. Phosphorylation is an important modification for the regulation of protein activity. The researchers also show that this phosphorylation affects the sensitivity of the liver to insulin. The researchers have thus discovered a new signalling pathway that regulates insulin sensitivity in the body.

Nerve cells in the hypothalamus

The effect on the liver is mediated by a group of nerve cells called POMC neurons. These neurons are activated within seconds by the sight and smell of food, signalling the liver to prepare for the incoming nutrients. The researchers also showed that the activation of POMC neurons alone is sufficient to adapt the mitochondria in the liver, even in the absence of food.

"When our senses detect food, our body prepares for food intake by producing saliva and digestive acid. We knew from previous studies that the liver also prepares for food intake. Now we have taken a closer look at the mitochondria in liver cells, because they are essential cell organelles for metabolism and energy production, and realised how surprisingly fast this adaptation takes place," explains Sinika Henschke, first author of the study.

Jens Brüning, head of the study and director at the Max Planck Institute for Metabolism Research: "Our study shows how closely the sensory perception of food, adaptive processes in the mitochondria and insulin sensitivity are linked. Understanding these mechanisms is also important because insulin sensitivity is impaired in type 2 diabetes mellitus".

Jens Brüning is also a research group leader at the CECAD Cluster of Excellence in Ageing Research at the University of Cologne and Director of the Department of Endocrinology, Diabetology and Preventive Medicine at Cologne University Hospital as well as associated partner in the German Center for Diabetes Research (DZD).

Originalpublikation: Food perception promotes phosphorylation of MFFS131 and mitochondrial fragmentation in liver. Henschke, S., Nolte, H., Magoley, J. et al. Science 2024; 384: 438-446.

Quelle: DZD

 

Dedicated memory tests on smartphones enable the detection of “mild cognitive impairment”, a condition that may indicate Alzheimer’s disease, with high accuracy. Researchers from DZNE, the Otto-von-Guericke University Magdeburg and the University of Wisconsin-Madison in the United States who collaborated with the Magdeburg-based company neotiv report these findings in the scientific journal npj Digital Medicine. Their study is based on data from 199 older adults. The results underline the potential of mobile apps for Alzheimer’s disease research, clinical trials and routine medical care. The app that has been evaluated is now being offered to medical doctors to support the early detection of memory problems.

Memory problems are a key symptom of Alzheimer’s disease. Not surprisingly, their severity and progression play a central role in the diagnosis of Alzheimer’s disease and also in Alzheimer’s research. In current clinical practice, memory assessment is performed under the guidance of a medical professional. The individuals being tested have to complete standardized tasks in writing or in conversation: for example, remembering and repeating words, spontaneously naming as many terms as possible on a certain topic or drawing geometric figures according to instructions. All these tests necessarily require professional supervision, otherwise the results are not conclusive. Thus, these tests cannot be completed alone, for example at home.

Prof. Emrah Düzel, a senior neuroscientist at DZNE’s Magdeburg site and at University Magdeburg as well as entrepreneur in medical technology, advocates a new approach: “It has advantages if you can carry out such tests on your own and only have to visit the doctor’s office to evaluate the results. Just as we know it from a long-term ECG, for example. Unsupervised testing would help to detect clinically relevant memory impairment at an earlier stage and track disease progression more closely than is currently possible. In view of recent developments in Alzheimer’s therapy and new treatment options, early diagnosis is becoming increasingly important.”

Comparison between remote at-home and supervised in-clinic testing

In addition to his involvement in dementia research, Düzel is also “Chief Medical Officer” of “neotiv”, a Magdeburg-based start-up with which the DZNE has been cooperating for several years. The company has developed an app with which memory tests can be carried out autonomously with no need for professional supervision. The software runs on smartphones and tablets, and has been scientifically validated; it is used in Alzheimer’s disease research and is now also offered as a digital tool for medical doctors to support the detection of mild cognitive impairment (MCI). Although MCI has little impact on the affected individuals daily living, they have nevertheless an increased risk of developing Alzheimer’s dementia within a few years.

Dr. David Berron, research group leader at DZNE and also co-founder of neotiv explains: “As part of the validation process, we applied these novel remote and unsupervised assessments as well as an established in-clinic neuropsychological test battery. We found that the novel method is comparable to in-clinic assessments and detects mild cognitive impairment, also known as MCI, with high accuracy. This technology has enormous potential to provide clinicians with information that they cannot obtain during a patient vist to the clinic.” These findings have now been published in the renowned scientific journal “npj Digital Medicine”.

Participants from Germany and the USA

A total of 199 women and men over the age of 60 participated in the current study. They were located either in Germany or the USA and were each involved in one of two long-term observational studies, both of which address Alzheimer’s – the most common dementia: DZNE’s DELCODE study (Longitudinal Cognitive Impairment and Dementia Study) and the WRAP (Wisconsin Registry for Alzheimer's Prevention) study of the University of Wisconsin-Madison. The study sample reflected varying cognitive conditions as they occur in a real world situation: It included individuals who were cognitively healthy, patients with MCI and others with subjectively perceived but not measurable memory problems. The diagnosis was based on established assessments that included e. g. memory and language tasks. In addition, all participants completed multiple memory assessments with the neotiv app over a period of at least six weeks, using their own smartphones or tablets – and wherever it was convenient for them. “We found that a majority of our WRAP participants were able to complete the unsupervised digital tasks remotely and they were satisfied with the tasks and the digital platform,” says Lindsay Clark, PhD, neuropsychologist and lead investigator of the Assessing Memory with Mobile Devices study at the University of Wisconsin-Madison.

Remembering images and detecting differences

“Assessments with the neotiv app are interactive and comprise three types of memory tasks. These address different areas of the brain that can be affected by Alzheimer’s disease in different disease stages. Many years of research have gone into this,” Düzel explains. Essentially, these tests involve remembering images or recognizing differences between images that are presented by the app. Using a specially developed score, the German-US research team was able to compare the results of the app with the findings of the established in-clinic assessments. “Our study shows that memory complaints can be meaningfully assessed using this digital, remote and unsupervised approach,” says Düzel. “If the results from the digital assessment indicate that there is memory impairment typical of MCI, this paves the way for further clinical examinations. If test results indicate that memory is within the age-specific normal range, individuals can be given an all-clear signal for the time being. And for Alzheimer’s disease research, this approach provides a digital cognitive assessment tool that can be used in clinical studies – as is already being done in Germany, the USA, Sweden and other countries.”

Outlook

Further studies are in preparation or already underway. The novel memory assessment is to be tested on even larger study groups, and the researchers also intend to investigate whether it can be used to track the progression of Alzheimer’s disease over a longer period of time. Berron: “Information about how quickly memory declines over time is important for medical doctors and patients. It is also important for clinical trials as new treatments aim to slow the rate of cognitive decline.” The cognitive neuroscientist describes the challenges: “To advance such self-tests, a patient’s clinical data must be linked to self-tests outside the clinic, in the real-world. This is no easy task, but as our current study shows, we are making progress as a field.”

Original publication: A Remote Digital Memory Composite to Detect Cognitive Impairment in Memory Clinic Samples in Unsupervised Settings using Mobile Devices. Berron, D., Glanz, W., Clark, L. et al. npj Digit. Med. 2024 7, 79.

Source: DZNE

Social isolation and loneliness are major social problems. Their negative impact on mental health has been exacerbated worldwide by the Covid-19 pandemic. Researchers at the Central Institute of Mental Health (CIMH) in Mannheim, in collaboration with scientists from the Karlsruhe Institute of Technology (KIT), the Ruhr University Bochum (RUB), and the University of Bern, have investigated the extent to which physical activity can mitigate the negative effects of social isolation on well-being. The interdisciplinary research team, including scientists from the DZPG, has published the results of its study in the journal Nature Mental Health.

Positive effects of exercise

The study shows that people who were currently alone in their daily lives reported a comparatively lower level of well-being, but this increased when they were physically active. The data suggest that physical activity, such as walking for one hour at a speed of five kilometers per hour, can compensate for the current "social-affective deficit". In further exploratory analyses, the researchers describe that this beneficial effect of exercise persisted even at lower levels of physical activity and during pandemic-related restrictions. Investigations of the subjects' brain function also showed that people at increased neural risk for depression and loneliness benefited particularly from a more physically active lifestyle.

The study included 317 young adults and a second group of 30 adults who were examined during the Covid-19 pandemic. The researchers used a variety of methods for their study, including accelerometers, smartphones with electronic diaries, and brain imaging. This approach allowed the researchers to study the complex interplay between social contact, physical activity, and psychological well-being in everyday life, and to identify the associated brain functions.

Dynamic interplay

"Previous studies have mostly examined social contact and physical activity independently. Our study extends this knowledge by showing a dynamic interplay between these two factors in everyday life, which has an impact on affective well-being," says Anastasia Benedyk from the Department of Psychiatry and Psychotherapy at the ZI, who is the first author of the study together with Prof. Dr. Markus Reichert (CIMH and RUB).

Prof. Dr. Dr. Heike Tost, also from the Department of Psychiatry and Psychotherapy at the CIMH, adds: "The results suggest that physical activity can be used as an effective and accessible strategy to counteract the psychological effects of loneliness and improve public health".

Original publication: Real-life behavioral and neural circuit markers of physical activity as a compensatory mechanism for social isolation. Benedyk, A., Reichert, M., Giurgiu, M. et al. Nat Mental Health 2.2024:337–342.

Source: DZPG

The German Center for Paediatric and Adolescent Medicine (DZKJ) will become a new partner of the German Centers for Health Research (DZG) from June 1, 2024. This expands the number of DZG centers to eight. The aim of the German Centers for Health Research is to combat particularly common diseases - the widespread diseases - more effectively. The DZG were established on the initiative of the Federal Ministry of Education and Research (BMBF).

The nationally organized and networked research center will receive 30 million euros in funding from the Federal Ministry of Education and Research during the two-year start-up phase. The DZKJ office will be located at the University Medical Center Göttingen (UMG). The aim of the Göttingen partner site is to develop personalized medicine specifically for children and adolescents with neurological and developmental diseases.

Childhood and adolescence are key developmental phases in which the fundamental course for lifelong health is set. Another German Center for Health Research has been established to ensure the best possible disease detection and treatment as well as comprehensive care according to the latest state of research during this time.

Seven partner sites: Berlin, Göttingen, Greifswald/Rostock, Hamburg, Leipzig/Dresden, Munich and Ulm

The future German Center for Paediatric and Adolescent Medicine (DZKJ) pools the specialist expertise of university hospitals and universities at seven partner locations: Berlin, Göttingen, Greifswald/Rostock, Hamburg, Leipzig/Dresden, Munich and Ulm. Experts from various fields of research work together here on a cross-thematic basis.

In addition to university hospitals and universities, non-university research institutions such as Max Planck Institutes, Fraunhofer Institutes, Helmholtz and Leibniz Centers are also involved. After the start-up phase, long-term institutional funding is to follow.

Prof. Dr. Jutta Gärtner, Göttingen, spokesperson for the DZKJ and Director of the Department of Paediatric and Adolescent Medicine at the University Medical Center Göttingen (UMG), explains the mission of the new center: “Paediatric and adolescent medicine encompasses the entire complex spectrum of diseases of the developing organism. Cross-organ disease mechanisms and treatment approaches play a central role in this. Thanks to the close collaboration between the experts at the DZKJ, the latest research findings will benefit young patients directly and promptly."

Cross-site platforms and DZKJ Academy

The interdisciplinary research covers a broad spectrum from rare genetic diseases, immunity, inflammation, infection, development of the central nervous system and neurological diseases, obesity, early determinants of health and disease, psychosocial and mental health to community medicine.

Platforms for clinical studies, research data management and new biotechnological methods, for example omics technologies, gene and cell therapies, will be established across all locations. A joint platform will promote cooperation with the German Center for Mental Health (DZPG), which is also being established.

The establishment of a DZKJ-wide patient and test subject cohort and the preparation of joint clinical studies and biobanks are important cross-sectional activities. The promotion of young scientists is of particular importance. Special training and mentoring programs will be developed as part of an overarching DZKJ Academy.

Affected people get involved in research

Children and adolescents as well as their parents are involved in research activities and the organization of the center from the very beginning. A particular focus is on empowering patients to become directly involved in the planning and implementation of research projects. Parent representative Anja Bratke and patient representative Stephan Kruip say: “We see an opportunity for both the research projects and the children and their parents to benefit from this new type of patient involvement. Children and adolescents are often already little experts when it comes to their own illness. Involving them and their parents in the newly founded DZKJ in such an innovative way is a major step towards strengthening patients' rights."

The DZKJ will make an important contribution to international cutting-edge research in the field of pediatric and adolescent medicine through interdisciplinary and innovative research. The aim is to ensure that children and adolescents in Germany receive optimal, state-of-the-art disease detection and treatment at all stages of their development.

Source: Joint press release of the University Medical Center Göttingen (UMG) and the German Center for Paediatric and Adolescent Medicine (DZKJ)

Patients have regular check-ups during and after lung cancer treatment to see whether the treatment is successful in the long term - or whether the cancer has returned. This is extremely important for both the treating physicians as well as the patients. A DZL research team has now discovered that the presence of the protein glycodelin in the blood indicates that a therapy is failing. This leads to some interesting conclusions.

Immunotherapies reactivate the body's own defences to fight a tumor. For non-small cell lung cancer (NSCLC), the survival times of patients treated in this way improved significantly. However, immunotherapy does not work for everyone. This suggests that additional mechanisms are involved.

Early results from Heidelberg

In earlier studies, scientists from the DZL site TLRC Heidelberg had already established that lung tumors produce the mRNA for glycodelin. Women with such tumors have a reduced survival rate. The physiological function of the glycodelin protein is to downregulate the maternal immune system of the uterus at the beginning of pregnancy. This is necessary to prevent it from recognizing the fetus as ‘foreign’. Tumors take advantage of this function by upregulating the production of glycodelin.

New findings on the mode of action of glycodelin

The aim of the new study was to investigate the underlying mechanisms of action of glycodelin in more detail. To this end, the Heidelberg researchers teamed up with scientists from the Borstel Research Center at the DZL site ARCN. Together, they were able to show that glycodelin binds strongly to certain subgroups of immune cells and thus influences various signaling pathways. Genes associated with inflammatory processes or the tumor environment were deregulated. Multiplex immunofluorescence staining, which allows the parallel detection and spatial localization of a large number of surface proteins, revealed that these immune cells include CD8-positive T lymphocytes. It is precisely these T cells - also known as "cytotoxic" - that play an important role in immunotherapies. It is conceivable that glycodelin blocks their effect and thus contributes to treatment failure.

Clinical potential

Further studies have now shown that glycodelin can also be found in the blood of both male and female patients. There was a clear link between high levels and early tumor recurrence - but only in women. Glycodelin therefore contributes to the suppression of the immune system and thus to the recurrence of the tumor.

This marks out Glycodelin as an important sex-specific marker that could be used in therapy monitoring. It is also conceivable to develop an antibody that blocks glycodelin. In this way, the tumor could be deprived of one of the options of evading therapy. Dr. Sebastian Marwitz from the Research Center Borstel is optimistic: "The results on the sex-specific role of glycodelin offers an excellent first step towards precision medicine and targeted treatment for female patients."

Successful cooperation within the DZL

These new insights gained were achieved through a collaboration between scientists from the German Cancer Research Center, the Thoraxklinik and the University of Heidelberg (all three belong to DZL site TLRC) and the Research Center Borstel (DZL site ARCN). It was published earlier this month in the journal Translational Research. The publication’s first author, Sarah Richtmann, was supported by the Mobility Grant Program of the DZL Academy.

Original publication: The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancer. Richtmann, S., Marwitz, S., Muley, T. et al. Transl Res. 2024 Mar 13;(24):1931-5244.

Source: DZL

Over 12 million people worldwide suffer from a chronic infection with the hepatitis D virus. This most severe viral liver disease is associated with a high risk of dying from liver cirrhosis and liver cancer. It is caused by the hepatitis D virus (HDV), which uses the surface proteins of the hepatitis B virus (HBV) as a vehicle to specifically enter liver cells via a protein in the cell membrane—the bile salt transporter protein NTCP. This cell entry can be prevented by the active agent bulevirtide, which is approved as a drug under the name Hepcludex.

An international research team has now succeeded in deciphering the molecular structure of bulevirtide in complex with the HBV/HDV receptor NTCP at the molecular level. The research results published in the renowned journal Nature Communications pave the way for more targeted and effective treatments for millions of people chronically infected with HBV/HDV.

The entry inhibitor bulevirtide is the first and currently only approved drug (under the drug name Hepcludex) for the treatment of chronic infections with the hepatitis D virus. The active agent effectively inhibits the replication of hepatitis D viruses and leads to a significant improvement in liver function. However, the exact mechanism by which bulevirtide interacts with the virus entry receptor on the surface of the liver cells—the bile salt transporter protein NTCP (short for: sodium taurocholate cotransporting polypeptide)—and thereby inhibits the entry of the viruses into the cells was previously unknown.

In order to understand the molecular interaction of bulevirtide and NTCP at the molecular level, the researchers first generated an antibody fragment that specifically recognises the NTCP-bulevirtide complex and makes it accessible for analysis when bound to nanoparticles. This complex was then analysed using cryo-electron microscopy, which allowed to visualise structural details with atomic resolution. The research results represent a milestone in understanding both the interaction of HBV and HDV with their cellular entry receptor NTCP and the mechanism of cell receptor blockade by bulevirtide.

How bulevirtide blocks the cell entry receptor NTCP

The analysis showed that bulevirtide forms three functional domains in the interaction with the HBV/HDV receptor NTCP: a myristoyl group that interacts with the cell membrane on the outside of the cell; an essential core sequence ('plug') that fits precisely into the bile salt transport tunnel of the NTCP like the bit of a key into a lock; and an amino acid chain that stretches across the extracellular surface of the receptor, enclosing it like a brace. 

"The formation of a 'plug' in the transport tunnel and the associated inactivation of the bile salt transporter is so far unique among all known virus-receptor complexes. This structure explains why the physiological function of the NTCP is inhibited when patients are treated with bulevirtide," says Prof Stephan Urban, DZIF Professor of Translational Virology and Deputy Coordinator of the DZIF research area Hepatitis, in whose laboratory at Heidelberg University the active agent bulevirtide was developed. 

"Thanks to the structural details of the interaction with bulevirtide, we have also gained insights that enable the development of smaller active agents—so-called peptidomimetics—with improved pharmacological properties. Our structural analysis also lays the foundation for the development of drugs that are not only based on peptides and possibly enable oral administration," adds the co-author of the study, Prof Joachim Geyer from the Institute of Pharmacology and Toxicology at Justus Liebig University Giessen. 

Evolutionary adaptation of hepatitis B viruses to host species

The structural analysis also helped to decode an important factor in the species specificity of hepatitis B and D viruses. According to the findings of the analysis, the amino acid at position 158 of the NTCP amino acid chain plays an essential role in virus-receptor interaction. A change in the amino acid at this position prevents the binding of HBV/HDV. This explains why certain Old World monkeys, such as macaques, cannot be infected by HBV/HDV. 

"Our findings enable a deeper understanding of the evolutionary adaptation of human and animal hepatitis B viruses to their hosts and also provide an important molecular basis for the development of new and targeted drugs," adds co-author Prof Dieter Glebe, DZIF scientist at the Institute of Medical Virology at Justus Liebig University Giessen. 

"Our research results are an important step in the fight against hepatitis D and B. By understanding the structure of bulevirtide and its binding to NTCP, we can potentially develop more targeted and effective treatments for millions of people chronically infected with HBV/HDV," says Prof. Kaspar Locher, last author of the publication and head of the internationally renowned structural biology team at ETH Zurich, summarising the study results.

Original publication: Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP. Liu, H., Zakrzewicz, D., Nosol, K. et al. Nat Commun. 2024 Mar 20;15(1):2476.

Source: DZIF

The results of a study led by the DKTK partner site in Tübingen give reason to hope that a newly developed drug could start a new era in oncological liver surgery and liver transplantation. The drug could also have the potential to significantly improve the treatment of acute and chronic liver diseases. The results of the study have now been published in the renowned scientific journal Cell.

The drug candidate "HRX-215" is a so-called MKK4 inhibitor, which inhibits the MKK4 protein found in liver cells and increases the regeneration of liver cells. The preclinical and phase I trials, led by Prof. Dr. Lars Zender (Medical Director, Department of Medical Oncology and Pneumology, University Hospital Tübingen and scientist at the German Consortium for Translational Cancer Research (DKTK), partner site Tübingen), were made possible by a collaboration between scientists from Tübingen, the Tübingen start-up HepaRegeniX and researchers from the Mayo Clinic (USA).

Therein, preclinical studies in mouse and pig models have shown that the increased liver regeneration caused by the inhibitor HRX-215 allows liver surgery that was previously not possible. Until now, it has not been possible to surgically remove all of the affected tissue in advanced liver tumors, for example, as this would lead to liver failure in the remaining liver. The extended partial liver removal made possible by HRX-215 could lead to the complete removal of advanced liver tumors. In addition, the active substance could be able to provide more people with a life-saving liver transplant. A phase I study in 48 healthy volunteers showed excellent tolerability of the drug.

Liver disease as a growing health problem

Liver disease is a global health problem and is responsible for more than two million deaths per year. The number of deaths has risen by 50 percent in recent decades and is expected to double in the next 20 years. Although the liver is one of the few organs that can regenerate itself, this property has its limits. Particularly in chronic and acute liver diseases or after the surgical removal of a large part of the organ, the liver cells can no longer regenerate sufficiently. The consequence is often fatal liver failure. Even today, the last resort for end-stage liver disease is a liver transplant. However, due to the shortage of donor organs, only ten percent of all affected patients can receive a life-saving liver transplant.

Clinical results give cause for hope

As there were previously no drugs that could increase the regeneration of a damaged liver, the published results with the new active ingredient HRX-215 are a milestone: "The positive results in terms of tolerability confirm our intention to be able to offer a drug in the future that has the potential to revolutionize the treatment of acute liver diseases," emphasizes Dr. Wolfgang Albrecht, CEO of the Tübingen-based start-up company HepaRegeniX. The current results and the spin-off of HepaRegeniX were largely made possible by Prof. Zender's groundbreaking discovery in 2013. "By inhibiting the kinase MKK4, the self-healing function of a damaged liver can be triggered," says first author Stefan Zwirner, summarizing the findings.

Possible solution to organ donation shortage?

"HRX-215 would not only be an urgently needed treatment option in the surgical removal of liver tumors, but could also help to overcome the major problem of organ shortage in the field of liver transplantation," Prof. Zender points out the possible applications. Live transplants from the smaller left part of the liver of a healthy donor would be a solution, as the removal of the liver poses only a low health risk for healthy donors. However, this part of the liver is often too small to take over the function of the liver removed from the recipient. "Due to the rapid enhancement of liver regeneration mediated by HRX-215, we assume that HRX-215 treatment would enable the safe transplantation of small left liver lobes in adults," continues Prof. Zender. However, further clinical studies must show this.

Academic center for drug development

"When we started developing an MKK4 inhibitor in 2017, none of us could have imagined that we would be able to start the first clinical trial just four years later and present the first results of the Phase I trial three years later," adds Prof. Stefan Laufer, whose research group carried out the medicinal chemistry work on the first MKK4 inhibitor. The development of MKK4 inhibitors is a success story and underlines the leading national and international role of the Tübingen site in the field of drug development and optimization. With the Cluster of Excellence iFIT (Image Guided and Functionally Instructed Tumor Therapies) and the Tübingen Center for Academic Drug Discovery & Development (TüCAD2), whose founder and spokesperson is Prof. Laufer, the university has a unique platform for the identification, validation and development of innovative drug candidates, which has already brought several candidates to first application in humans.

German-American cooperation

Before the active substance was tested on healthy volunteers in the Phase I study, it was used in animal models (mice and pigs). For the studies in pigs, we collaborated with the Mayo Clinic (USA) with Prof. Dr. Scott. L. Nyberg, an internationally renowned expert in the field of transplantation and regenerative medicine. His team was able to show that the use of HRX-215 increased liver regeneration in the animals and prevented liver failure, even after removal of 85 percent of the organ.

Original publication: First-in-class MKK4 Inhibitors enhance Liver Regeneration and prevent Liver Failure. Zwirner, S., Abu Rmilah, A.A., Klotz, S., Pfaffenroth, B. et al. Cell. 2024 Mar 28;187(7):1666-1684.e26

Source: DKTK

A research team at DZNE has been awarded around one million US dollars for the development of an innovative, AI-based method to measure the “choroid plexus” three-dimensionally in human brain scans. These finely branched brain structures are the main sources of the “cerebrospinal fluid” and thus of great significance for the function of the brain and spinal cord. It is also assumed that they play a role in various neurological diseases, including Alzheimer’s. The research project is funded by the US National Institutes of Health (NIH).

The “cerebrospinal fluid” (CSF) is a watery liquid that circulates in the brain and spinal cord. It carries nutrients and metabolic products, dampens shocks and largely originates from cavities deep inside the brain. The actual “springs” are complexly shaped appendages of the brain tissue that protrude into these cavities and the cerebrospinal fluid they contain. “Choroid plexus” is the technical term for the elongated, highly branched structures that produce the CSF. Every individual has four of them, some of which are interconnected. At the same time, these structures are relatively small; in adults they have a total volume similar to that of a sugar cube. “Such delicate brain structures are difficult to capture in living humans. That’s why we want to develop an AI-supported method that automatically identifies the choroid plexuses in brain scans so that their shape and dimensions can be precisely determined,” explains Prof. Martin Reuter, an expert in AI in image analysis and research group leader at DZNE. “Automated and precise measurements of these structures will help to better understand disease processes and normal brain changes over the course of life.”

Digital “dissection” of the brain

For this undertaking, the Bonn scientist and his team will draw on three-dimensional brain magnetic resonance images (MRI). This wil involve data from the NIH’s “Human Connectome Project” and from other sources. In total, data from around 700 participants will be included. Although computer algorithms exist in principle for the intended separation of the brain images into different areas – experts call this “segmentation” – they are too inaccurate for the choroid plexuses. “For these complicated brain structures, you need a specialized, fully automatic tool. We don’t have that in good quality yet. And segmentation by hand, where one marks the contours of the relevant tissue on the screen with a mouse click, is laborious and prone to errors,” says Reuter. “That’s why we aim to develop a method that can be used to efficiently and reliably evaluate large brain MRI data sets. Just as is required for studies with a large number of participants. These could be drug trials or studies on ageing, for example, such as the Rhineland Study of the DZNE here in Bonn.”

Five-year runtime

In this project, DZNE will cooperate closely with US institutions, in particular with the “Beth Israel Deaconess Medical Center” in Boston, a Harvard Medical School affiliate. At the end, a software based on advanced artificial intelligence shall be available that has “learned” through examples – so-called training data – to recognize the “springs of CSF” in MRI data. The development of the necessary algorithms, and their training and validation, are labor-intensive efforts. Already the selection and creation of suitable training data in advance is time-consuming. Therefore, the research project is scheduled for five years. Reuter is hoping for a digital instrument that will be widely used in research: “We are going to design our tool so that it works with data of different resolutions and from different types of brain scanners. We also plan to make the software freely available within the open source FastSurfer project for brain MRI analysis, developed at DZNE.”

Source: DZNE

People using anabolic steroids could be increasing their underlying risk of a heart condition called atrial fibrillation, a new study has found. The new research published in the Journal of Physiology conducted by an interdisciplinary consortium of clinicians and researchers led by the University of Birmingham and collaborators in Germany, including first author and DZHK Young member Dr Laura Sommerfeld.

The team found that male sex hormones, such as testosterone, also called androgenic anabolic steroids (AAS), which are misused for muscle building particularly among in young men can increase the risk of atrial fibrillation in individuals genetically predisposed to heart diseases.

Dr Laura Sommerfeld, Postdoctoral Researcher at the UKE Hamburg, who completed her PhD at the Institute of Cardiovascular Sciences at the University of Birmingham focusing on this work is lead author of the study.

“Our study can significantly contribute to understanding the impact on the heart health of young men who misuse anabolic steroids to increase muscle mass.", says Sommerfeld. "Recent reports have shown that young men in particular are being targeted on social media such as TikTok being sold testosterone products, but we have shown how the misuse of steroids carries a specific risk that many people will not be aware of.”

Professor Larissa Fabritz, Chair of Inherited Cardiac Conditions at UKE Hamburg and Honorary Chair in the Institute of Cardiovascular Sciences at the University of Birmingham adds: “Heart muscle diseases like ARVC affect young, athletic individuals and can lead to life-threatening heart rhythm disturbances. Atrial fibrillation is a common condition in the general population. Elevated testosterone levels can result in an earlier onset of these diseases.”

Disrupted cell connection

The scientists examined potential effects on a condition called arrhythmogenic right ventricular cardiomyopathy (ARVC), which is genetically determined and primarily attributed to disruptions in the formation of cell connections critical for heart muscle stability. They initially confirmed, based on clinical patient data from UHB and elsewhere, that ARVC occurs more frequently and severely in men than in women.

In laboratory experiments, they discovered that six weeks of AAS intake, combined with impaired cell connections, could lead to reduced sodium channel function in heart tissue and a slowing of signal conduction within the atria.

Dr Andrew Holmes, co-author and Assistant Professor in the Institute of Clinical Sciences at the University of Birmingham says: "This work implies that young male individuals with key inherited genetic changes have a greater risk of developing electrical problems in the heart in response to anabolic steroid abuse."

Source: DZHK

The 6th Joint Dresden DZG Symposium took place on March 26, 2024: The three German Centers for Health Research (DZG) located in Dresden play a significant role on Dresden's biomedical campus, with 250 researchers and clinicians, a budget of over 11 million euros, and 240 publications in 2023 alone. They include the German Cancer Consortium (DKTK), the German Center for Neurodegenerative Diseases (DZNE), and the Paul Langerhans Institute Dresden (PLID) of the German Center for Diabetes Research (DZD).

Scientists from both university and non-university research institutions work together interdisciplinary in the individual centers to bring new research results into application more quickly. This is necessary because of the persistently high prevalence of common diseases such as cancer, metabolic disorders, and neurodegenerative conditions.

Despite their different research areas, the three centers have much in common when it comes to developing new therapeutic approaches or research methods. The long-term networking that has now existed for many years at the Dresden site offers outstanding opportunities to jointly develop new innovative research strategies.

Once a year, the three centers organize the Joint Dresden DZG Symposium, which took place for the sixth time on March 26, 2024, and was mainly hosted by the DKTK this time. The symposium, designed as a platform for exchange among Dresden scientists and physicians, took place at the MTZ with over 100 participants.

The importance of the DZG for Saxony was underlined by the presence of Sebastian Gemkow, Saxon State Minister for Science, who gave a welcoming speech in addition to Esther Troost, Dean of the Faculty of Medicine at TU Dresden and Mechthild Krause, spokesperson for the DKTK partner site Dresden.

Subsequently, the three local spokespersons of the DZG – besides Mechthild Krause, Michele Solimena (DZD/PLID) and Gerd Kempermann (DZNE) – presented their institutions and current research highlights. Gerd Kempermann then took the opportunity, on behalf of all present, to thank our longtime ministerial supporter, Annerose Beck, for her unwavering and tireless commitment to the Dresden DZG.

In his presentation on the national activities of the German Centers for Health Research, Triantafyllos Chavakis spoke about a groundbreaking immunological project, which has been funded by the DZG Innovation Fund (DZGIF), in which researchers from the various DZG have been able to apply for research funding for a joint project on a specific topic since 2022.

We have already implemented this concept of DZG-overarching research support locally since 2020 with a popular and successful seed funding for cross-DZG projects, which are intended to promote new translational activities between the DZG in Dresden. At this year's symposium, the awardees of the last funding round (News link) had the opportunity to present the progress of their projects to the audience.

This year also included again the one-minute poster flash talks. 19 young scientists took the opportunity to present their projects briefly and concisely. Afterwards, the conference participants had the opportunity to engage in discussions with the young researchers at their respective posters.

The keynote presentation was given by Jakob N. Kather (EKFZ Dresden). With his lecture on "AI in Medicine", he provided a fascinating insight into the possible applications and still existing limitations of artificial intelligence in medical diagnostics and therapy.

Finally, Gerd Kempermann had the pleasure and honor of opening the next call for DZG-overarching project proposals and inviting everyone to the 7th Joint Dresden DZG Symposium at the DZNE in 2025.

Source: DKTK

After weight loss, people with overweight and obesity express more of the protein Kallistatin* in subcutaneous white adipose tissue. This was demonstrated by researchers from the DZD in a recent study. In addition, Kallistatin improves metabolism and could open up new therapeutic options for people with obesity and type 2 diabetes in future. The results have now been published in Molecular Metabolism.

An increasing number of people are developing type 2 diabetes and obesity. These are highly complex and multifaceted diseases. In order to treat them sustainably, new approaches to therapy are needed. Clinical studies on humans have shown that heavily overweight individuals produce less Kallistatin. Kallistatin is a protein that has various effects in the body. Among other things, it is involved in counteracting inflammation and healing wounds. The role that Kallistatin plays in glucose metabolism and its potential suitability as a therapeutic target are currently being investigated by researchers from the German Center for Diabetes Research (DZD), the Institute for Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Munich at the Eberhard-Karls-University of Tübingen, and the Department of Diabetology, Endocrinology and Nephrology at the University Hospital Tübingen.

Kallistatin Expression Increases After Weight Loss

To this end, they measured Kallistatin expression in subcutaneous white adipose tissue in 47 individuals with overweight to obesity before and after weight loss. The result: Kallistatin expression increases after weight loss.

Kallistatin Improves Hepatic Insulin Sensitivity

Additionally, the researchers examined the effect of the protein in an animal model. In the process, they observed that human Kallistatin improves hepatic insulin sensitivity in diet-induced obese mice.

“Our results suggest that Kallistatin may be an interesting, yet challenging, therapeutic target for people with obesity and insulin resistance” says lead author Leontine Sandforth. “Because Kallistatin has insulin-sensitizing effects in the liver, it should be investigated as a potential liver-specific target for emulating the beneficial effects of weight loss and potentially treating type 2 diabetes and obesity” adds last author Prof. Andreas Birkenfeld.

The Most Important Results at a Glance

*Kallistatin (KST)

Kallistatin is a circulating, broadly acting human protein. It plays a role in healing injuries and preventing illnesses, for example. Clinical studies in humans revealed reduced KST levels in obesity. However, the exact role of this protein in the regulation of blood sugar and energy metabolism in the setting of insulin resistance and type 2 diabetes is not yet fully understood. Researchers are working to decode these relationships in order to find new approaches for treating metabolic disorders.

Original publication: Role of human Kallistatin in glucose and energy homeostasis in mice. Sandforth, L., Brachs, S., Reinke, J. et al. Mol Metab. (82) 2024 Apr.

Source: DZD

A significant advancement in the research of childhood asthma was achieved by an interdisciplinary group of the ALLIANCE (ALL Age Asthma) cohort of the DZL, led by Helmholtz Munich and the Technical University of Munich (TUM). The study, whose findings were published in the prestigious American Journal of Respiratory and Critical Care Medicine, demonstrates a correlation between a specific gene variant in children and the development of asthma. This milestone opens new avenues for therapeutic approaches.

The causes of asthma in childhood have not yet been fully understood. Approximately one in three children develops an early form of asthma in the first years of life, with 80 percent of them exhibiting a genetic variant on chromosome 17. These children are prone to recurrent viral infections, which could later lead to asthma. The mechanisms behind this gene variant have been unknown, leading to only symptomatic treatment.

Researchers examined samples of nasal mucosa from children with early asthma. They found an increased expression of the protein GSDMB, which is produced in greater quantities due to the gene variant. This protein plays a crucial role in the children's immune response and leads to disrupted interferon release, which is significant for the cellular response to viral infections. Additionally, there were indications that the balance of natural killer cells is disrupted, negatively impacting the barrier function of the nasal mucosa. Researchers speculate that this makes children more susceptible to viral infections and allows allergens to penetrate more easily, potentially leading to the long-term development of asthma. The goal now is to correct the immune defect in the children's airways. To achieve this, they are working on new medications in the form of inhalation sprays that support virus defense by stimulating the epithelial barrier for a more appropriate response.

Thus, the research findings not only provide insights into the causes of childhood asthma but also offer promising prospects for the development of targeted therapies and preventive measures.

Original publication: 17q21 Variants Disturb Mucosal Host Defense in Childhood Asthma. Jakwerth, CA., Weckmann, M., Illi, S. et al. Am J Respir Crit Care Med. 2023 Dec 8.

Source: DZL